/주식/BNGO
BNGO

BNGO

USD

Bionano Genomics Inc. Common Stock

$3.700+0.030 (0.817%)

실시간 가격

Healthcare
Medical Instruments & Supplies
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$3.670

고가

$3.780

저가

$3.660

거래량

0.05M

기업 기본 정보

시가총액

12.4M

산업

Medical Instruments & Supplies

국가

United States

거래 통계

평균 거래량

0.14M

거래소

NCM

통화

USD

52주 범위

저가 $2.68현재가 $3.700고가 $52.2

관련 뉴스

Analyst Upgrades

Maxim Group Upgrades Bionano Genomics to Buy, Announces $8 Price Target

Maxim Group analyst Jason McCarthy upgrades Bionano Genomics from Hold to Buy and announces $8 price target.

더 보기
Maxim Group Upgrades Bionano Genomics to Buy, Announces $8 Price Target
GlobeNewswire

Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress

SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents the first full

더 보기
Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress
GlobeNewswire

Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report

더 보기
Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025
GlobeNewswire

International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers

SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome

더 보기
International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers